Video

Educated Patient Lung Cancer Summit On-Demand: Dec. 12, 2020

Author(s):

CURE Media Group

View all three sessions of the CURE Educated Patient Lung Cancer Summit here!

View all three sessions of the CURE Educated Patient Lung Cancer Summit here!

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
Imiage of two doctors with text.
Image of two doctors and text.
Image of patient and doctor.
Image of two doctors with text.
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of thumbnail.
Related Content
The FDA approved Zegfrovy for advanced NSCLC with EGFR exon 20 mutations after chemotherapy: stock.adobe.com.
July 2nd 2025

Zegfrovy FDA Approved for EGFR Exon 20 Non-Small Cell Lung Cancer

Spencer Feldman
The FDA approved Zegfrovy for advanced non-small cell lung cancer with EGFR exon 20 mutations after chemotherapy.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Sue McCarthy received diagnoses of breast cancer in 2001 and lung cancer in 2018. Catch up on all of Sue's blogs here!
June 26th 2025

Caring for Patients With Cancer Beyond Remission

Sue McCarthy
I entered remission from lung cancer 5.5 years ago, but faced a tough road readjusting, with ongoing physical, mental and emotional challenges.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Image of two doctors with text.
June 22nd 2025

Experts Impart Notable Information and Updates for Those With Blood Cancers

Dr. Joshua K. Sabari Dr. Nausheen Ahmed
The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.
Image of two doctors with text.
June 20th 2025

Advancements Reshape Treatment for Non-Small Cell Lung Cancer

Ryan Scott
Dr. Prantesh Jain and Dr. Joshua Sabari delved into the numerous advances in NSCLC following 2025 ASCO, highlighting the REZILIENT-1 and NeoADAURA trials.